Adviezen commissie BOM

Terug naar lijst
  • Auteur
  • NVMO-commissie BOM
  • Printdatum
  • 14-03-2002
  • E-pubdatum
  • 14-03-2002
  • Bron
  • Medische Oncologie

Paclitaxel en docetaxel als eerstelijns chemotherapie bij het gemetastaseerd mammacarcinoom

Lees online Download PDF

De trials die tot dusver zijn gepubliceerd leveren vooralsnog onvoldoende argumenten om paclitaxel of docetaxel als eerstelijns palliatieve chemotherapie bij het gemetastaseerde mammacarcinoom te gebruiken.

Referenties

  1. Bishop JF, Dewar J, Toner GC, et al. ‘Initial paclitaxel improves outcome compared with CMFP combination chemotherapy as front-line therapy in untreated metastatic breast cancer’. Journal of Clinical Oncology 1999;17:2355-2364
  2. Paridaens R, Biganzoli L, Bruning P, et al. ‘Paclitaxel versus doxorubicin as firstline single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer randomized study with cross-over’. Journal of Clinical Oncology 2000;18:724-733.
  3. Jassem J, Pienkowski T, Pluzanska A, et al. ‘Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomized phase III multicenter trial’. Journal of Clinical Oncology 2001;19:1707-1715.
  4. Nabholtz JM, Senn HJ, Bezwoda WR, et al. ‘Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline- containing chemotherapy. The 304 Study Group’. Journal of Clinical Oncology 1999;17:1413-1424.
  5. Chan S, Friedrichs K, Noel D, et al. ‘Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. The 303 Study Group’.Journal of Clinical Oncology 1999;17:2341-2354.
  6. Sjoström J, Blomqvist C, Mouridsen H, et al. ‘Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomised phase III study with cross-over on progression by the Skandinavian Breast Group’. European Journal of Cancer 1999;35:1194-1201.
Lees meer